A treatment that once meant cutting into a patient’s back may eventually arrive through nothing more than a syringe. Engineers and clinicians in Abu Dhabi have produced a nerve-stimulating implant roughly the size of a seed that carries no battery, trails no wires, and is delivered by ordinary needle injection.
The work comes from NYU Abu Dhabi in partnership with Cleveland Clinic, and appears in the peer-reviewed journal Science Advances, as reported by Khaleej Times. Positioned alongside a chosen nerve, the implant emits measured electrical pulses that alter the way that nerve relays signals throughout the body — the technique known as neuromodulation. All of its power comes from an external source rather than an internal cell, and its output can be tuned on the spot, by a physician now or potentially by the patient later, according to how the body is responding.
What sets the approach apart is what it leaves out. The senior author framed the change in terms of access and simplicity. “This work represents a shift in how we think about treating nerve-related conditions,” said Prof Khalil Ramadi, Assistant Professor of Bioengineering at NYU Abu Dhabi and NYU Tandon. “By creating a device that can be injected rather than surgically implanted, we are making these therapies simpler, safer, and more accessible, while still maintaining precise control over nerve activity.”
Compare that with the hardware in use today. A spinal cord stimulator, for instance, calls for an operation to route wiring toward the spine, plus a second cut — commonly in the back or the abdomen — to house a battery unit. Recovery typically runs four to six weeks while tissue settles around the leads and the generator, and the battery itself eventually runs down, lasting a few years before a follow-up procedure swaps it out. Stripping away the incisions, the leads, and the power pack is precisely the problem the new design sets out to solve.
The implant also answers a tracking limitation. Because it shows up on routine ultrasound and CT imaging, clinicians can verify exactly where it sits and keep an eye on it afterward — a check that conventional implants do not readily allow.
For now the device sits firmly in the laboratory and preclinical phase. Researchers report that it held steady performance under lifelike conditions and steered nerve stimulation with precision, and that it switched on nerves successfully within living tissue, an outcome they read as evidence it could function in practice. Human testing has not happened, and it is not on offer as a therapy.
The first author cast the result as a way to close a longstanding divide in care. “This technology has the potential to bridge the gap between non-invasive therapies and traditional implants,” said Dr Mohamed Elsherif, Research Associate at NYU Abu Dhabi and first author of the study. “It opens the door to treatments that are both effective and easy to deliver, which could significantly improve patient care.”
Dr Sawsan Abdel-Razig, Chief Academic Officer at Cleveland Clinic Abu Dhabi, pointed to the collaboration itself, noting that joining clinical knowledge with engineering research is what lets safer, gentler treatments progress from early science toward eventual use in patients.
The patient population in question reaches far past the Emirates. The International Association for the Study of Pain estimates that low back pain by itself touches some 30 to 40 per cent of adults at any moment — the chronic pain category that neuromodulation is meant to address. Commercial appetite mirrors that scale: a Fortune Business Insights report put the value of the global market for these devices at roughly $7.25 billion in 2026, with a projected climb to $13.78 billion by 2034, propelled mainly by interest in gentler substitutes for the implants now on the market.
Should the device clear additional study, advance into human trials, and satisfy regulators, its developers expect it to cut down on the major operations now tied to managing chronic pain and movement disorders.
